Global Primary Immunodeficiency Market Size, Share, Forecast Report, 2020-2027

The global Primary Immunodeficiency market garnered revenue around USD 5.8 Billion in 2019 and projected to reach USD 9.8 Billion in 2027, with at a compound annual growth rate (CAGR) 6.3% throughout the estimate period from 2020 to 2027. The primary immunodeficiency disorders (PIDs) are clinically heterogeneous disorders, the majority of which arise from genetic defects in immunologically relevant genes. Primary immune deficiencies are present in a heterogeneous manner, and a high index of suspicion is required to diagnose primary immune deficiencies. Any patient with a suspected or proven primary immunodeficiency disorder (PID) should be referred to the care of a clinical immunologist. Immune dysregulation phenotypes of PID are commonplace and include multiorgan autoimmunity, malignancy (particularly hematological), and autoinflammatory pathology such as periodic fever syndromes.

In terms of type, the global primary immunodeficiency market has been segmented into antibody deficiency, cellular deficiency, and innate immune. Antibody deficiency has been categorized into agammaglobulinaemia, common variable immune deficiency, selective IgA deficiency, IgG subclass deficiency, and others. Cellular deficiency has been classified into Ataxia Telangiectasia, hyper IgM syndromes, Wiskott-Aldrich syndrome, DiGeorge syndrome, and others. Innate immune has been split into complement deficiencies, hyper IgE syndrome, and others. The antibody deficiency segment captured the largest market share in 2019. The segment is expected to expand at the highest CAGR during the forecast period, owing to rise in need and demand for diagnosis by patients.

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Primary Immunodeficiency market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Primary Immunodeficiency market growth.

The global Primary Immunodeficiency market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

he global primary immunodeficiency market include Shire plc, CSL Behring, Kedrion Biopharma Inc, Grifols, S.A., Octapharma, China Biologic Products Holdings, Inc., Biotest AG, Sanquin, and LFB SA.

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

Global Primary Immunodeficiency Market: Segmentation                                                                                                                                                                             

Primary Immunodeficiency Market, by Type

  • Antibody Deficiency
    • Agammaglobulinaemia
    • Common Variable Immune Deficiency
    • Selective IgA Deficiency
    • IgG Subclass Deficiency
    • Others
  • Cellular Deficiency
    • Ataxia Telangiectasia
    • Hyper IgM Syndromes
    • Wiskott-Aldrich Syndrome
    • DiGeorge Syndrome
    • Others
  • Innate Immune
    • Complement Deficiencies
    • Hyper IgE Syndrome
    • Others

Primary Immunodeficiency Market, by Treatment type

  • Immunoglobuline Replacement Therapy
  • Antibiotic Therapy
  • Stem cell and Gene Therapy
  • Others (Vaccines, Nutritional Supplements, and Others)

Regional Analysis and Forecast

Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Rest of EU
  • Asia Pacific
    • China
    • India
    • Japan
    • Southeast Asia
    • Rest of APAC
  • Central & South America
    • Brazil
    • Argentina
    • Rest of Central & South America
  • Middle East and Africa
    • UAE
    • Saudi Arabia
    • Rest of MEA